Literature DB >> 2061116

Response of glioblastoma cell lines to low dose rate irradiation.

L A Marin1, C E Smith, M Y Langston, D Quashie, L E Dillehay.   

Abstract

Glioblastoma U251 and U87 cells irradiated with single fraction high dose rate radiation (1.1 Gy/min) were relatively insensitive to inactivation of colony forming ability, similar to other glioblastoma cell lines. Initial rates of cell kill with continuous low dose rate irradiation (0.075 Gy/hr to 0.49 Gy/hr) were low, but at times greater than 20 hours and with dose rates of 0.25 Gy/hr or higher, the rate of cell kill increased. Population doubling times for these cell lines were about 24 hours, suggesting that cell cycle redistribution may be responsible for the increased sensitivity. DNA histograms obtained by flow cytometry support this hypothesis, with cells accumulating in the G2 and M phases of the cell cycle. These results suggest that low dose rate irradiation may be effective in treating glioblastomas. Optimization of time intervals between radiation treatments as well as dose rates used for glioblastoma patients may be influenced by these findings, resulting in better integration of continuous low-dose-rate irradiation (radioactive antibodies and implants) and high-dose-rate irradiation (fractionated external beam) into therapeutic programs.

Entities:  

Mesh:

Year:  1991        PMID: 2061116     DOI: 10.1016/0360-3016(91)90788-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.

Authors:  J A Williams; L E Dillehay; K Tabassi; E Sipos; C Fahlman; H Brem
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

2.  Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation.

Authors:  Yiting Lim; Mohammad Hedayati; Akil A Merchant; Yonggang Zhang; Hsiang-Hsuan M Yu; Michael B Kastan; William Matsui; Theodore L Deweese
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-22       Impact factor: 7.038

3.  Anti-Kaposi's sarcoma and antiangiogenic activities of sulfated dextrins.

Authors:  M Thornton; L Barkley; J C Mason; S Shaunak
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 4.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  Outcomes From Whole-Brain Reirradiation Using Pulsed Reduced Dose Rate Radiation Therapy.

Authors:  Adam R Burr; Henry Ian Robins; Robert Adam Bayliss; Andrew M Baschnagel; James S Welsh; Wolfgang A Tomé; Steven P Howard
Journal:  Adv Radiat Oncol       Date:  2020-07-08

6.  Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme.

Authors:  David A Larson; Jeffrey M Suplica; Susan M Chang; Kathleen R Lamborn; Michael W McDermott; Penny K Sneed; Michael D Prados; William M Wara; M Kelly Nicholas; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

7.  Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.

Authors:  Jörgen Carlsson; Veronika Eriksson; Bo Stenerlöw; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-23       Impact factor: 9.236

8.  Salvage radiosurgery for selected patients with recurrent malignant gliomas.

Authors:  Miguel Martínez-Carrillo; Isabel Tovar-Martín; Mercedes Zurita-Herrera; Rosario Del Moral-Ávila; Rosario Guerrero-Tejada; Enrique Saura-Rojas; Juan Luis Osorio-Ceballos; Juan Pedro Arrebola-Moreno; José Expósito-Hernández
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.